Citation Impact
Citing Papers
Current Status of Augmentation and Combination Treatments for Major Depressive Disorder: A Literature Review and a Proposal for a Novel Approach to Improve Practice
2006
Medication Augmentation after the Failure of SSRIs for Depression
2006 Standout
Acute and Longer-Term Outcomes in Depressed Outpatients Requiring One or Several Treatment Steps: A STAR*D Report
2006 Standout
Clinical and Neurobiological Effects of Tianeptine and Paroxetine in Major Depression
2003
Influence of Patients’ Requests for Direct-to-Consumer Advertised Antidepressants
2005 Standout
Sertraline versus imipramine to prevent relapse in chronic depression
2001
Pharmacological treatment of negative symptoms of schizophrenia: therapeutic opportunity or Cul‐de‐sac?
2007
Glutamate receptor ion channels
2005 Standout
Glutamate Receptor Ion Channels: Structure, Regulation, and Function
2010 Standout
Open Forum: Effectiveness Versus Efficacy of Second-Generation Antipsychotics: Haloperidol Without Anticholinergics as a Comparator
2005
Comparison of systematic and narrative reviews: the example of the atypical antipsychotics
2003
Estrogen Receptors: How Do They Signal and What Are Their Targets
2007 Standout
Comparative efficacy of antipsychotics in the treatment of schizophrenia: A critical assessment
2005
DESIGN AND REPORTING MODIFICATIONS IN INDUSTRY-SPONSORED COMPARATIVE PSYCHOPHARMACOLOGY TRIALS
2002
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
2005 Standout
Relapse Prevention in Schizophrenia With New-Generation Antipsychotics: A Systematic Review and Exploratory Meta-Analysis of Randomized, Controlled Trials
2003
Olanzapine Treatment of Psychotic and Behavioral Symptoms in Patients With Alzheimer Disease in Nursing Care Facilities
2000
Why Olanzapine Beats Risperidone, Risperidone Beats Quetiapine, and Quetiapine Beats Olanzapine: An Exploratory Analysis of Head-to-Head Comparison Studies of Second-Generation Antipsychotics
2006
Central nervous system control of food intake and body weight
2006 StandoutNature
The 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations and Summary Statements
2009
Schizophrenia
2009 Standout
Expert Committee Recommendations Regarding the Prevention, Assessment, and Treatment of Child and Adolescent Overweight and Obesity: Summary Report
2007 Standout
Pharmacological Treatment of the Overweight Patient
2007
Childhood obesity: public-health crisis, common sense cure
2002 Standout
Effects of Antipsychotic Medications on Psychosocial Functioning in Patients With Chronic Schizophrenia: Findings From the NIMH CATIE Study
2007
SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials
2013 Standout
Evaluation of Outcomes With Citalopram for Depression Using Measurement-Based Care in STAR*D: Implications for Clinical Practice
2006 Standout
Prevalence of Neuropsychiatric Symptoms in Dementia and Mild Cognitive Impairment
2002 Standout
Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation
2015 Standout
A Risk-Benefit Assessment of Anti-Obesity Drugs
1999
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 1: Update 2012 on the acute treatment of schizophrenia and the management of treatment resistance
2012
Publication Bias in Antipsychotic Trials: An Analysis of Efficacy Comparing the Published Literature to the US Food and Drug Administration Database
2012
Effectiveness and Cost of Olanzapine and Haloperidol in the Treatment of Schizophrenia<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>
2003
Childhood Sexual Abuse as a Risk Factor for Depression in Women: Psychosocial and Neurobiological Correlates
1999
Optimal Dosing of Atypical Antipsychotics in Adults: A Review of the Current Evidence
2002
Remission in Schizophrenia: Proposed Criteria and Rationale for Consensus
2005 Standout
Linking “big” personality traits to anxiety, depressive, and substance use disorders: A meta-analysis.
2010 Standout
Food and metabolic signalling defects in a Caenorhabditis elegans serotonin-synthesis mutant
2000 StandoutNatureNobel
Predictors of nonresponse to treatment in primary care patients with dysthymia
2002
Sex and gender: modifiers of health, disease, and medicine
2020 Standout
Regulation of serotonin re-uptake transporter mRNA expression by ovarian steroids in rhesus macaques
1998
Psychosis as a State of Aberrant Salience: A Framework Linking Biology, Phenomenology, and Pharmacology in Schizophrenia
2002 Standout
Effectiveness of Second-Generation Antipsychotics in Patients With Treatment-Resistant Schizophrenia: A Review and Meta-Analysis of Randomized Trials
2001
Central nervous system control of food intake
2000 StandoutNature
Gut–brain axis: how the microbiome influences anxiety and depression
2013 Standout
Dose Response and Dose Equivalence of Antipsychotics
2004
"Schizotaxia": Clinical Implications and New Directions for Research
2001
Nonalcoholic Steatohepatitis: Summary of An Aasld Single Topic Conference
2003 Standout
Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement
1999 Standout
Rethinking schizophrenia
2010 StandoutNature
Ovarian steroids and serotonin neural function
1998
Power failure: why small sample size undermines the reliability of neuroscience
2013 Standout
Flupenthixol versus Risperidone: Subjective Quality of Life as an Important Factor for Compliance in Chronic Schizophrenic Patients
2003
Alzheimer's disease
2006 Standout
Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range
2014 Standout
A decision analysis model to assess the feasibility of the early detection of psychosis in the general population
2004
Antipsychotics and QT prolongation
2003
Estrogen receptors in the human forebrain and the relation to neuropsychiatric disorders
2001
Long-term Pharmacotherapy of Obesity 2000
2001
Antipsychotic-Induced Weight Gain: A Comprehensive Research Synthesis
1999 Standout
Predictors of response in depression
2003
Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials
1999
Alzheimer's Disease
2004 Standout
The new and evolving pharmacotherapy of schizophrenia
2003
An analysis of the effect of funding source in randomized clinical trials of second generation antipsychotics for the treatment of schizophrenia
2004
How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials
2008
Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life
2000
Hypothalamic serotonin in control of eating behavior, meal size, and body weight
1998
Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis
2013 Standout
Estrogen Actions in the Central Nervous System1
1999 Standout
A Meta-analysis of the Efficacy of Second-Generation Antipsychotics
2003
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and Elaboration
2007 Standout
Increased Risk of Antipsychotic-Related QT Prolongation During Nighttime
2011
Antipsychotics in Adults With Schizophrenia: Comparative Effectiveness of First-Generation Versus Second-Generation Medications
2012
Fluorine in medicinal chemistry
2007 Standout
Comparative Benefits and Harms of Second-Generation Antidepressants: Background Paper for the American College of Physicians
2008
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
Risperidone versus typical antipsychotic medication for schizophrenia
2003
Pharmacological interventions for somatoform disorders in adults
2014 Standout
Sex differences in the psychopharmacological treatment of depression
2016
Bad is Stronger than Good
2001 Standout
Practice parameter: Management of dementia (an evidence-based review) [RETIRED]
2001 Standout
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and Elaboration
2007 Standout
Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine
1997
Current and Potential Drugs for Treatment of Obesity
1999
2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death
2015 Standout
ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease
2006 Standout
Fluorine in Pharmaceuticals: Looking Beyond Intuition
2007 StandoutScience
TheC. elegansPOU-domain transcription factor UNC-86 regulates thetph-1tryptophan hydroxylase gene and neurite outgrowth in specific serotonergic neurons
2002 StandoutNobel
Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial
1997
3-(4-Fluoropiperidin-3-yl)-2-phenylindoles as High Affinity, Selective, and Orally Bioavailable h5-HT2A Receptor Antagonists
2001
Birth and Death of Bone Cells: Basic Regulatory Mechanisms and Implications for the Pathogenesis and Treatment of Osteoporosis*
2000 Standout
Interventions for enhancing medication adherence
2014 Standout
Effects on prolongation of Bazett’s corrected QT interval of seven second-generation antipsychotics in the treatment of schizophrenia: a meta-analysis
2010
Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 1993 British Association for Psychopharmacology guidelines
2000
The Timing of Normal Puberty and the Age Limits of Sexual Precocity: Variations around the World, Secular Trends, and Changes after Migration
2003 Standout
The Metabolic Syndrome
2008 Standout
Haloperidol versus placebo for schizophrenia
2013
2008 Focused Update Incorporated Into the ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease
2008 Standout
Reported Methodologic Quality and Discrepancies between Large and Small Randomized Trials in Meta-Analyses
2001 Standout
Works of S.H. Hamilton being referenced
A cost-effectiveness clinical decision analysis model for schizophrenia.
1998
Fluoxetine in Medically Stable, Depressed Geriatric Patients
1997
Double-Blind Comparison of Olanzapine Versus Risperidone in the Treatment of Schizophrenia and Other Psychotic Disorders
1997
Functional outcomes in schizophrenia: a comparison of olanzapine and haloperidol in a European sample
2000
Clinical Response Predictors in a Double-Blind, Placebo-Controlled Trial of Fluoxetine for Geriatric Major Depression
1995
Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial
1996
Predicting Response to Fluoxetine in Geriatric Patients With Major Depression
1995
Clinical and Economic Outcomes of Olanzapine Compared With Haloperidol for Schizophrenia
1999
Efficacy and Safety of Long‐Term Fluoxetine Treatment of Obesity ‐ Maximizing Success
1995
Comparative efficacy of olanzapine and haloperidol for patients with treatment-resistant schizophrenia∗∗See accompanying Editorial, in this issue.
1999
A Double-Blind, Randomized, Placebo-Controlled Trial of Olanzapine in the Prevention of Psychotic Relapse
2003
Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial
1997
Olanzapine versus Placebo and Haloperidol
1996
Olanzapine Versus Placebo and Haloperidol: Quality of Life and Efficacy Results of the North American Double-Blind Trial
1998
Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders: Quality of life and clinical outcomes of a randomized clinical trial
1999
Olanzapine vs. risperidone in the treatment of psychosis
1997
Estrogen Replacement and Response to Fluoxetine in a Multicenter Geriatric Depression Trial
1997
Estrogen Replacement and Response to Fluoxetine in a Multicenter Geriatric Depression Trial
1997
Relapse prevention with olanzapine
2000
Olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders
1998
Olanzapine versus risperidone in the treatment of psychosis. Preliminary report
1997